Проскар

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Проскар

Quick Facts

Property Description
Active ingredient Finasteride
Form Film-coated tablets
Pharmacological class 5-alpha reductase inhibitor
General purpose Hormonal pathway modulation (DHT reduction)
Origin Synthetic 4-azasteroid

What Type of Medicine is Проскар (Finasteride)?

Проскар is a prescription-only medicine that contains the active substance Finasteride, classified as a specific enzyme inhibitor. Finasteride belongs to the pharmacological class of 5-alpha reductase inhibitors and is provided as an oral dosage form. The structure of this medication is defined by its origin as a synthetic 4-azasteroid compound, which is characteristic of its chemical composition. Its designation as a 5-alpha reductase inhibitor is clinically recognized for its highly targeted approach to regulating steroid metabolism, delivering a consistent and systemically available agent.

Composition and Physical Form of Проскар

The formulation of Проскар consists of Finasteride as the single active ingredient, prepared as film-coated tablets for oral administration. The tablets contain solid pharmaceutical excipients necessary for stability and proper absorption within the digestive system. The choice of the oral dosage form is essential for systemic distribution, allowing the synthetic compound to reach the intended enzyme targets throughout the body. The medication's identity is thus linked to the precise delivery of this 5-alpha reductase inhibitor via the oral route.

The General Purpose of a 5-Alpha Reductase Inhibitor

The general purpose of using this type of medicine is to reduce the influence of the potent androgen dihydrotestosterone (DHT) by controlling its formation. This biological action is achieved through the preferential inhibition of 5-alpha reductase type 2. This means the medicine is scientifically proven to target the specific enzyme that converts testosterone into DHT. By blocking this enzymatic process, Finasteride systematically causes a significant reduction of DHT concentration in the serum and target tissues. This targeted hormonal modulation is the high-level objective, relevant in scenarios involving androgen-sensitive tissues.

Regulatory References

  1. Finasteride Label
  2. Finasteride (StatPearls)

What side effects are possible with Проскар?

Possible Side Effects and Safety Information

Finasteride's official safety profile is classified by government regulatory documents based on the types and frequency of reported adverse reactions.

Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions, classified as Common, primarily involve the reproductive system and include decreased libido, ejaculation disorder (including decreased volume), and impotence (erectile dysfunction). Effects classified as Uncommon include breast enlargement (gynecomastia) and breast tenderness, and rash. Other adverse events, such as depression, testicular pain, palpitations, and sustained sexual dysfunction, are also documented but are listed with a Frequency Not Known.

Serious Safety Considerations and Restrictions

Regulatory agencies have noted specific risks concerning malignancies. Finasteride is associated with an officially documented risk of male breast cancer and, specifically at the 5 mg dose, an increased incidence of high-grade prostate cancer. Safety restrictions strictly dictate that the medicine is contraindicated in women who are or may become pregnant. Furthermore, women of childbearing potential should not handle crushed or broken tablets due to the potential risk to a male fetus.

Contextual and Duration-Related Safety Patterns

Reports exist of sexual adverse events, including libido and ejaculation disorders, that continued after the discontinuation of the medicine. The official labeling also notes that Finasteride reduces serum Prostate Specific Antigen (PSA) concentration, a critical factor for prostate cancer screening, which necessitates the doubling of the measured PSA value for accurate interpretation of test results.

Overdose and Emergency Response

The official regulatory documentation for finasteride (Проскар) defines the overdosage profile primarily by the findings from controlled clinical studies demonstrating high tolerance.

Scope Element Official Regulatory Statement
Documented overdose presentations No adverse effects were observed in human subjects who received single doses up to 400 mg or multiple doses up to 80 mg/day for three months.
Emergency-response statements No specific treatment for an overdose with finasteride can be formally recommended until further clinical experience is obtained.
Classification Element Official Regulatory Statement
Antidote information The official prescribing information does not identify a specific antidote or pharmaceutical reversal agent.
Dose-related factors Doses up to 400 mg (single exposure) and 80 mg/day (repeated exposure over three months) are cited as the upper bounds for demonstrated human tolerance.

Official overdose statements:

  • Patients have received single doses of finasteride up to 400 mg without the documentation of adverse clinical effects.
  • No specific treatment or antidote is currently recommended by regulatory authorities for finasteride overexposure.
  • The official documentation does not list specific procedural, monitoring, or population-specific considerations.

Connection to the overall overdose profile: The regulatory profile emphasizes the high tolerance observed in clinical trials, establishing a significant safety margin rather than defining a specific toxic syndrome. This lack of a defined adverse effect pattern or specific antidote necessitates that any suspected overexposure be immediately addressed by a healthcare professional for clinical evaluation.

Therapeutic Uses of Проскар

Support for Symptomatic Benign Prostatic Hyperplasia (BPH)

This medication is commonly used in adult males for the management of the chronic condition of prostate enlargement, which causes symptoms that interfere with daily functioning. The medication is applied in addressing symptom clusters like a weakened urinary stream, the frequent need to urinate, and the sensation of incomplete bladder emptying. The primary therapeutic support contributes to improved urinary flow and the easing of these bothersome symptoms, which assists with maintaining functional stability. The medication is considered relevant for managing Benign Prostatic Hyperplasia and Male Pattern Hair Loss. Continued management may be part of symptomatic management used in conditions where functional stability becomes affected, which supports the patient during difficult episodes by easing distress.

Management of Male Pattern Hair Loss (Androgenetic Alopecia)

Проскар is applied in the dermatological domain to address the progressive, hereditary thinning and loss of hair on the scalp in men. The therapeutic support is relevant for easing symptoms related to progressive hair thinning and may assist with managing hair density. This supportive relief helps in managing symptoms related to progressive hair thinning, which supports general well-being during symptomatic phases.


QuickFact Block

Quick Fact: Relief for Prostatic and Hair Symptoms Description
Primary Target Conditions Benign Prostatic Hyperplasia (BPH) and Androgenetic Alopecia.
Main Symptom Cluster Symptoms related to organ-specific functional stress and progressive hair thinning.
Patient Benefit Supports functional stability and helps with managing hair density.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Проскар (finasteride 5 mg) is indicated only for use in men to treat the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate).


Who Can Use Проскар?

Adult Men diagnosed with Benign Prostatic Hyperplasia (BPH) are the primary users. Treatment is generally long-term and requires regular monitoring by a healthcare provider, including periodic Prostate Specific Antigen (PSA) blood tests. It may be prescribed alone or in combination with an alpha-blocker to manage BPH symptoms.


Who Cannot Use Проскар?

Проскар is contraindicated and must not be used by:

  • Women, especially those who are pregnant or who may become pregnant, due to the significant risk of causing birth defects in a male fetus.
  • Children and adolescents under 18 years of age, as the safety and efficacy have not been established in this population.
  • Anyone with a known hypersensitivity or allergic reaction to finasteride or any other ingredients in the tablet.

Additionally, women should not handle broken or crushed tablets, as the active ingredient can be absorbed through the skin, posing a potential risk during pregnancy. Patients with existing liver disease should use caution and discuss their condition with their doctor, as finasteride is metabolized extensively by the liver.

What should I know about interactions with other medicines?

The official regulatory profile for Finasteride provides specific documentation regarding its interaction potential, focusing primarily on its metabolic clearance pathway and the resulting absence of widespread clinically important interactions.

Interaction Classifications (High-Level)

Classification Official Regulatory Statement
Interaction severity classification: No drug interactions of clinical importance have been identified in regulatory documents [FDA Prescribing Information].
Interaction-related restrictions: No contraindicated combinations are formally listed based on interaction risk with Finasteride alone [FDA Prescribing Information].

Official Interaction Statements

  • Lack of Clinically Meaningful Interactions: Studies involving co-administration with common compounds resulted in no clinically meaningful interactions with Finasteride. These tested compounds included antipyrine, digoxin, propranolol, theophylline, and warfarin [FDA Prescribing Information].
  • Metabolic Pathway Identification: Finasteride is primarily metabolized in the liver via the cytochrome P450 3A4 (CYP3A4) enzyme subfamily. However, Finasteride does not appear to affect the overall CYP450-linked drug-metabolizing enzyme system [FDA Prescribing Information].
  • Food and Timing Requirements: The regulatory label notes that no clinically important interaction with food is documented, and there are no specific timing-based separation rules required for administration.
  • Population-Specific Caution: A formal note of caution is required for administration to patients with liver function abnormalities, reflecting the drug's extensive hepatic metabolism [FDA Prescribing Information].

This structure confirms that while the metabolic pathway is documented for clearance, Finasteride does not significantly interfere with the metabolism of other co-administered substances, minimizing the need for interaction-based restrictions.

Mechanism of Action

Selective Inhibition of the 5α-Reductase Enzyme

This domain covers the drug's primary action: functioning as a specific, competitive inhibitor of the Type II 5α-reductase enzyme. By forming a stable complex with this enzyme, the drug immediately suppresses the conversion of Testosterone into the androgen Dihydrotestosterone (DHT), initiating the necessary hormonal cascade.

Modulation of Androgen Metabolism and Tissue Atrophy

The core pathway effect involves the systemic and local reduction of DHT, which is the principal mediator of prostate cell proliferation. The removal of this key growth signal triggers the physiological process of cellular atrophy and regression within the target tissue, directly translating the molecular inhibition into a structural change.

The Delayed Effect on Organ Volume and Pressure

This mechanistic sequence culminates in a measurable reduction of the prostate gland's overall volume. Because this physiological effect relies on sustained tissue de-growth rather than rapid functional modulation, the resulting change in organ size modulates the physical pressure exerted on the urethra, thereby altering the dynamic flow characteristics within the urinary system over time.

Dosage and Administration Information

Official Administration Guidelines for Proscar (5 mg Finasteride)

The following details describe the standard administration protocols for this medication.

Administration Detail Official Instruction
Route of Administration Oral (by mouth)
Standard Dosing Schedule One 5 mg tablet daily (once a day)
Timing Relative to Meals May be administered with or without meals
Tablet Preparation Swallow the tablet whole. Do not crush or break the tablet
Missed Dose Rule Skip the missed dose and continue with the regular dosing schedule. Do not take a double dose to make up for the missed one

Procedural and Long-Term Use Instructions

  1. Take the medicine at approximately the same time each day to maintain a consistent routine.
  2. The product is intended for long-term administration. It may take six months or more of daily use to fully assess whether the desired response has been achieved.
  3. Special Handling Precaution: The coated tablets prevent contact with the active ingredient during normal handling. However, pregnant women or women who may potentially be pregnant must not handle crushed or broken tablets due to the potential risk of absorption of the active ingredient.

Dosage Adjustment Notes:

  • Elderly Patients: No dosage adjustment is required.
  • Renal Impairment: No dosage adjustment is required for patients with varying degrees of renal insufficiency.
  • Pediatric Use: The 5 mg formulation is not indicated for use in children.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action and Efficacy

Research evaluated the drug in relation to specific mechanisms of action. Research evaluated the drug's activity in various chronic pain conditions.

  • Impact on Neuropathic Pain: One randomized, double-blind study explored outcomes of the drug in chronic neuropathic pain over a specific period. One trial observed a change in reported pain intensity among participants. A subsequent phase 3 trial evaluated measurement endpoints, including the percentage of participants reporting a specific change in pain score.

  • Citations: (Study A), (Study D)


Safety and Tolerability

Clinical trials conducted safety assessments that monitored for adverse events. Adverse events are categorized by frequency and severity.

  • Side Effect Profile: Common adverse events reported during clinical investigations included dizziness, drowsiness, and dry mouth. More serious, but rare, adverse events were also documented and tracked.

  • Comparisons and Initial Dosing: Clinical reports assessed the adverse event profile alongside those of comparator treatments. Research protocols often started participants at a specific low dose to monitor initial responses.

  • Cardiac Risk Assessment: Specific research populations, including those with pre-existing heart conditions, were examined to assess the presence of cardiac events during treatment.

  • Citations: (Study B), (Study F)


Auxiliary Outcomes

Beyond primary study endpoints, researchers explored additional measurements related to patient health.

  • Sleep and Concomitant Medication: Additionally, studies explored potential associations between the drug and changes in reported sleep quality and the use of concomitant analgesic medication.

  • Inflammation: Preliminary research evaluated changes observed in markers of inflammation during the study period.

  • General Chronic Pain Syndromes: The body of evidence explores the drug's activity across several chronic pain syndromes.

  • Citations: (Study C), (Study E)

Key Studies & References

  1. Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double-blind, placebo-controlled, pilot study (Study C / Study E - pain, inflammation, auxiliary outcomes)
  2. Finasteride delays atherosclerosis progression in mice and is associated with a reduction in plasma cholesterol in men (Study F - Cardiac/Inflammation Association)
  3. Association between finasteride with subjective memory deficits: a study from the NHANES and FAERS databases (Neuropsychiatric and memory adverse events)

Frequently Asked Questions (FAQ)

Common questions about Проскар (FAQ)


Q: What exactly is benign prostatic hyperplasia (BPH)?

A: Authoritative medical sources, such as those from the National Institutes of Health (NIH), describe BPH as an enlarged prostate gland that is not cancerous (meaning it is benign). The condition is defined by hyperplasia, which means an excess of cell growth within the prostate.


Q: Is Проскар classified as a type of medicine known as an anti-androgen?

A: No. The official product documentation explicitly states that the active ingredient in Проскар has no anti-androgenic effects. The medicine works differently by targeting and inhibiting a specific enzyme called 5-alpha reductase, rather than blocking androgen receptors.


Q: What happens to the prostate gland when treatment with Проскар is discontinued?

A: Regulatory information indicates that the prostate gland's size, which typically decreases during treatment, is generally described as returning to its baseline value. Clinical data shows this return to baseline often occurs several months after the medicine is stopped.


Q: If a person stops taking Проскар, how quickly might BPH symptoms return?

A: Studies indicate that the beneficial effects of the medicine on BPH symptoms, such as improved urinary flow, are temporary. If treatment is stopped, these symptoms is expected to gradually reverse, typically within 6 to 12 months.


Q: Are breast lumps, pain, or nipple discharge listed as serious side effects to watch for?

A: Yes, official safety information advises patients to promptly report any changes in their breasts, such as lumps, pain, or nipple discharge, to their healthcare provider. These signs are important to report promptly because official warnings address the risk of male breast cancer.


Q: What is gynecomastia and is it a possible side effect listed in official documents?

A: Regulatory documents list side effects that may include enlarged or painful breasts, which are the common physical signs of gynecomastia. This indicates that this change has been reported in patients taking the medicine.


Q: What are the signs of a serious allergic reaction to Проскар?

A: Signs that may indicate a serious allergic (hypersensitivity) reaction include a skin rash or hives, or more critically, swelling of the face, lips, tongue, or throat. Patients should seek medical attention immediately if they experience trouble swallowing or throat tightness.


Q: What are the non-sexual side effects that may indicate a hypersensitivity reaction to Проскар?

A: Non-sexual signs of a hypersensitivity reaction that have been reported often include common allergic reactions like rash, hives (red, raised patches on the skin), or swelling in different areas of the body.


Q: Does Проскар impact fertility or sperm quality in men?

A: Postmarketing experience includes reports of concerns regarding poor sperm quality or infertility in some men taking the medicine. Official information notes that this change is often reported as reversible following discontinuation of the medicine.


Q: Is it true that a small amount of the drug can pass into semen?

A: Yes, clinical studies have detected very small, trace amounts of the active ingredient in the semen of men taking the medicine. Because of this, official product warnings exist to prevent exposure to pregnant women.


Q: What should be done immediately if a tablet is accidentally broken or crushed?

A: The tablets are coated to prevent exposure during normal handling. If a woman who is pregnant or may potentially be pregnant comes into contact with a crushed or broken tablet, official guidelines recommend that the contact area be washed immediately with soap and water.


Q: Why can men taking Проскар not donate blood?

A: Official blood donation guidelines restrict men from donating blood for at least one month after their last dose. This restriction is due to the potential risk the drug poses to a male fetus if the blood is transfused into a pregnant woman.


Q: Can Проскар cause a change in blood pressure?

A: Clinical trial summaries indicate that studies suggest there is no clinically significant effect on blood pressure caused by the medicine when used alone.


Q: Does Проскар affect the ability to drive or operate machinery?

A: There is no specific official warning that the medicine directly affects the ability to drive; however, because of potential side effects like dizziness or weakness, patients should observe how the medicine affects them before driving.


Q: Is it generally safe to drink alcohol while taking Проскар?

A: Official documents and interaction studies indicate that there are no known adverse interactions between the active ingredient in Проскар and alcohol.


Q: Can Проскар be taken with common over-the-counter pain relievers?

A: Official product information states that no drug interactions of clinical importance have been identified between this medicine and several common compounds, including some over-the-counter pain relievers, based on clinical testing.


Q: Does Проскар interact with herbal supplements like Saw Palmetto?

A: Reports indicate that there are no known interactions between the active ingredient and herbal supplements, such as Saw Palmetto, that would be considered clinically significant.


Q: Does Проскар contain common ingredients like lactose that patients should know about?

A: Yes, the tablet contains lactose monohydrate as an inactive ingredient. Official warnings describe the need for caution if a patient has rare hereditary problems of galactose intolerance.


Q: Do the side effects of Проскар generally lessen over time as the body adjusts?

A: Official reports based on long-term clinical data indicate that some common side effects, especially sexual ones, may diminish or subside over time with continued use.

How should Проскар be stored and disposed of?

Storage and Handling

Проскар (finasteride) tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), not exceeding 30 C. The medicine must be kept in its original container and the container must remain tightly closed to protect the tablets from light and moisture.

It is mandatory to store this medication out of the sight and reach of children.

Women who are pregnant or may potentially be pregnant must not handle crushed or broken tablets. The tablets are film-coated and prevent contact with the active ingredient during normal handling, provided they are not broken.

Disposal Requirements

Any unused or expired Проскар tablets must be disposed of according to local requirements. Medicines must not be disposed of via wastewater or household waste; consult a pharmacist about proper disposal methods, such as utilizing medicine take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Проскар found in:

A-Z Index: